Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications
Background The introduction of targeted therapies for the treatment of BRAF-mutated metastatic melanoma was associated with different cutaneous adverse events (AEs). Objectives To describe the type, frequency and severity of cutaneous AEs related to vemurafenib; to understand the association between...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-04-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1817838 |
| _version_ | 1797683580326903808 |
|---|---|
| author | Victor Desmond Mandel Matelda Medri Ausilia Maria Manganoni Laura Pavoni Francesco De Rosa Simone Ribero Flavia Foca Daniele Andreis Laura Mazzoni Serena Magi Francesca Farnetani Marco Palla Paola Ulivi Ignazio Stanganelli |
| author_facet | Victor Desmond Mandel Matelda Medri Ausilia Maria Manganoni Laura Pavoni Francesco De Rosa Simone Ribero Flavia Foca Daniele Andreis Laura Mazzoni Serena Magi Francesca Farnetani Marco Palla Paola Ulivi Ignazio Stanganelli |
| author_sort | Victor Desmond Mandel |
| collection | DOAJ |
| description | Background The introduction of targeted therapies for the treatment of BRAF-mutated metastatic melanoma was associated with different cutaneous adverse events (AEs). Objectives To describe the type, frequency and severity of cutaneous AEs related to vemurafenib; to understand the association between AEs and vemurafenib efficacy in terms of median overall survival (OS) and median progression-free survival (PFS); to identify molecular characteristics of long-term responders. Methods This observational, retrospective, monocentric study included all consecutive patients with unresectable stage III or stage IV melanoma and BRAF V600E mutation that started treatment with vemurafenib between May 2012 and May 2014. Results 62 patients with a median age of 56 years (range 26–82) were enrolled and received vemurafenib for a median period of 7.9 months (range 0.8–63.7). Among them, 45 patients presented at least one skin AE, 12 reduced the dosage due to cutaneous toxicity, and only one firstly reduced and after stopped the therapy. No specific molecular biomarkers were detected in long-term survivors. Conclusions Among long-term survivors, skin AEs seem to be less frequent and less severe. Results on multivariable analysis revealed that the presence of at least one G2 toxicity is a protective factor considering PFS, but not in terms of OS. |
| first_indexed | 2024-03-12T00:16:29Z |
| format | Article |
| id | doaj.art-f19d105505bf48ef9180b1443a9fa3f1 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:16:29Z |
| publishDate | 2022-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-f19d105505bf48ef9180b1443a9fa3f12023-09-15T14:28:49ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-04-013331368137510.1080/09546634.2020.18178381817838Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implicationsVictor Desmond Mandel0Matelda Medri1Ausilia Maria Manganoni2Laura Pavoni3Francesco De Rosa4Simone Ribero5Flavia Foca6Daniele Andreis7Laura Mazzoni8Serena Magi9Francesca Farnetani10Marco Palla11Paola Ulivi12Ignazio Stanganelli13Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Department of Dermatology, Spedali Civili di BresciaDepartment of Dermatology, Spedali Civili di BresciaImmunotherapy, Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Dermatologic Clinic, Department of Medical Sciences, University of TurinUnit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio EmiliaUnit of Melanoma, Cancer Immunotherapy & Innovative Therapies Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)Background The introduction of targeted therapies for the treatment of BRAF-mutated metastatic melanoma was associated with different cutaneous adverse events (AEs). Objectives To describe the type, frequency and severity of cutaneous AEs related to vemurafenib; to understand the association between AEs and vemurafenib efficacy in terms of median overall survival (OS) and median progression-free survival (PFS); to identify molecular characteristics of long-term responders. Methods This observational, retrospective, monocentric study included all consecutive patients with unresectable stage III or stage IV melanoma and BRAF V600E mutation that started treatment with vemurafenib between May 2012 and May 2014. Results 62 patients with a median age of 56 years (range 26–82) were enrolled and received vemurafenib for a median period of 7.9 months (range 0.8–63.7). Among them, 45 patients presented at least one skin AE, 12 reduced the dosage due to cutaneous toxicity, and only one firstly reduced and after stopped the therapy. No specific molecular biomarkers were detected in long-term survivors. Conclusions Among long-term survivors, skin AEs seem to be less frequent and less severe. Results on multivariable analysis revealed that the presence of at least one G2 toxicity is a protective factor considering PFS, but not in terms of OS.http://dx.doi.org/10.1080/09546634.2020.1817838melanomamelanoma, cutaneous malignantskin neoplasmsproto-oncogene proteins b-rafvemurafenibdrug-related side effects and adverse reactionslong term adverse effectslong-term carecancer survivorssurvivors |
| spellingShingle | Victor Desmond Mandel Matelda Medri Ausilia Maria Manganoni Laura Pavoni Francesco De Rosa Simone Ribero Flavia Foca Daniele Andreis Laura Mazzoni Serena Magi Francesca Farnetani Marco Palla Paola Ulivi Ignazio Stanganelli Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications Journal of Dermatological Treatment melanoma melanoma, cutaneous malignant skin neoplasms proto-oncogene proteins b-raf vemurafenib drug-related side effects and adverse reactions long term adverse effects long-term care cancer survivors survivors |
| title | Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications |
| title_full | Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications |
| title_fullStr | Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications |
| title_full_unstemmed | Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications |
| title_short | Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications |
| title_sort | long term vemurafenib therapy in advanced melanoma patients cutaneous toxicity and prognostic implications |
| topic | melanoma melanoma, cutaneous malignant skin neoplasms proto-oncogene proteins b-raf vemurafenib drug-related side effects and adverse reactions long term adverse effects long-term care cancer survivors survivors |
| url | http://dx.doi.org/10.1080/09546634.2020.1817838 |
| work_keys_str_mv | AT victordesmondmandel longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT mateldamedri longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT ausiliamariamanganoni longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT laurapavoni longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT francescoderosa longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT simoneribero longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT flaviafoca longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT danieleandreis longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT lauramazzoni longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT serenamagi longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT francescafarnetani longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT marcopalla longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT paolaulivi longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications AT ignaziostanganelli longtermvemurafenibtherapyinadvancedmelanomapatientscutaneoustoxicityandprognosticimplications |